WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections. But within weeks, investors were facing a much different picture—one that has now led to a securities class action lawsuit and an upcoming court deadline. Cohen Milstein Sellers & Toll PLLC, one of the nation’s top securities law firms, is calling on investors who purchased shares during the IPO to consider joining and seeking a ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during its initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities during the specified class period related to the company's IPO [3]. - Allegations include that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [6]. - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated the company's stock price [6].

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=146175&from=4CLASS PERIOD: This lawsuit ...

Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO, particularly regarding the company's financial sustainability and operational funding timeline [1][2]. Allegations - The complaint states that Zenas BioPharma materially overstated its ability to fund operations, claiming it could do so for twenty-four months instead of the actual twelve months as disclosed in its Form 10-Q filed on November 12, 2024 [2]. - Following the revelation of these omitted material facts, Zenas BioPharma's stock price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by June 16, 2025, and can remain absent class members if they choose not to participate [3]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud [2]. - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in Zenas to contact them for discussing legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [3][5]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [5]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who oversees the litigation on behalf of the class [6]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [7]. - For more information about the class action, interested parties can visit the firm's website or contact the partner directly [8].

Core Viewpoint - Zenas BioPharma, Inc. is facing a securities class action lawsuit due to alleged misrepresentation of its financial condition during its September 2024 IPO, with a significant drop in stock value following the revelation of its actual funding capabilities [4]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the District of Massachusetts, claiming that Zenas BioPharma overstated its operational funding period from 24 months to only 12 months [4]. - Following the disclosure of its true financial status, Zenas BioPharma's stock price fell nearly 49%, closing at $8.72 on April 15, 2025 [4]. - Investors who purchased shares during the IPO period are eligible to seek appointment as lead plaintiff, with a deadline set for June 16, 2025 [1]. Group 2: Role of Lead Plaintiff - The lead plaintiff will represent the class and guide the litigation strategy and settlement process, playing a significant role in overseeing the case [5]. - Any shareholder who purchased during the IPO can participate in recovery, but the lead plaintiff has a more active role [5]. Group 3: Cohen Milstein's Reputation - Cohen Milstein Sellers & Toll PLLC is recognized as a leading firm in securities fraud litigation, with over 100 attorneys across eight offices [6]. - The firm has a history of securing billions for investors, including a notable recovery of over $1 billion in the Wells Fargo Securities Litigation [7].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased or acquired Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost or obligation to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding during its initial public offering in September 2024 [2][3]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected net proceeds from the IPO [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period and were negligently prepared [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].